2018 PEPFAR Meeting

 

Date: 2018 Description: 2018 PEPFAR Meeting © PEPFAR

From July 20 – 22, 2018, more than 550 people from over 35 countries gathered in Amsterdam, the Netherlands, to review progress and share lessons on country efforts toward HIV/AIDS epidemic control.

Themes covered at the meeting included HIV testing modalities and approaches; treatment cascade, linkage, and retention; prevention in men as well as adolescent girls and young women; and lessons learned from Population-based HIV Impact Assessments. For the full agenda, click here.

Session Presentations

  • Opening Plenary (Keynote: Ambassador Deborah L. Birx, M.D.)
  • Welcome by USAID: Pathway to Indigenous Partners
  • Welcome by CDC: Where We Are in the Epidemic
  • Session 1: Lessons Learned from the Population-based HIV Impact Assessments (PHIAs)
  • Session 2: How Did We Get Here? PEPFAR at 15 Years
  • Session 3: Epidemic Control – Just the Beginning
    • Session 3A: Sustainable HIV Epidemic Control
    • Session 3B: Spending and Financing Post Epidemic Control
    • Session 3C: Using Rapid HIV Recency Assay to Rapidly Detect, Monitor, and Respond to Recent Infections in Central America
    • Session 3D: Getting to Zero, San Francisco: Using data to drive programs
    • Session 3E: Uncharted Territory: Approaching High-Prevalence Epidemic Control
  • Session 4: The Million Person Market – Applying Market-Based, Demand Side Approaches
    • Session 4A: The Private Sector Role in HIV/AIDS Care
    • Session 4B: The Private Sector: Friend or Foe?
    • Session 4C: Incorporating ARVs in the Social Security System: Dominican Republic
    • Session 4D: The Million Person Market: Applying Market-Based Demand Approached
  • Session 5: Advancing Policy – Panel with Ministers of Health
  • Session 6: The First 90 – Testing Modalities and Approaches
    • Session 6A: Improving HIV Testing Outcomes in Men
      • Session 6A.1: HTC in congregate settings: Jhpiego’s experience in Mozambique
      • Session 6A.2: Understanding & locating HIV at-risk men: Fraym using geospatial data and machine learning in Uganda
      • Session 6A.3: "Finding Adam:" Reaching Men Through HIV Index Testing and Partner Notification
      • Session 6A.4: Breaking Barriers to Uptake of Testing Among Men, Experiences from the STAR Initiative
      • Session 6A.5: Driving testing and treatment amongst men in South Africa
    • Session 6B: HIV Testing and Case Finding in Key Populations
      • Session 6B.1: HIV Testing and Case Finding in Key Populations: Moderated Discussion on Incentivized Case Finding
      • Session 6B.2: Key Population-Led Health Services to Enhance Case Finding in Thailand
      • Session 6B.3: "The Time Is Now:" Comprehensive Approach to HIV Testing and Linkage to Care for MSM in Brazil
    • Session 6C: Pediatric Testing Modalities
      • Session 6C.1: All Infants Should be Screened for HIV Exposure Status in Immunization Clinics in Countries with Generalized HIV Epidemics
      • Session 6C.2: Screening ALL Infants for HIV in Immunization Clinics: Too Little Too Late
      • Session 6C.3: Innovative testing strategies for pediatric case finding: Financial incentives, video-based information, and saliva-based testing
  • Session 7: The Second and Third 90s – Treatment Cascade, Linkage, and Retention
    • Session 7AAdult Men - Improving Retention in HIV Care Among Men Through Community ART Refills Groups: Experiences from Three Districts in Zimbabwe
    • Session 7B: Enrolling and Retaining Key Populations in Treatment Programs
      • Session 7B.1Enrolling and retaining Key Population in treatment: USAID Strengthening the Care Continuum Project
      • Session 7B.2Differentiated Service Delivery for Key Populations: Community Outreach Model
    • Session 7C: Pediatrics Treatment and Retention
      • Session 7C.1Improving Adolescent Viral Suppression Through Operation Triple Zero Initiative In Kenya
      • Session 7C.2: Raltegravir should be routinely used for treatment of HIV-infected newborns in low-resourced settings
      • Session 7C.3: Raltegravir should NOT be routinely used for treatment of HIV-infected newborns in low-resourced settings
  • Session 8
    • Session 8A: TB Preventive Therapy – Rethinking pathways to save lives
    • Session 8B: Transition to TLD – Impact on Programs and People
      • Session 8B.1Modeling future ART regimen policy in sub-Saharan Africa
      • Session 8B.2Neural Tube Defect Safety Signal: Limitations of Current Evidence
      • Session 8B.3South Africa and TLD Introduction
      • Session 8B.4CDC Director's Update: TLD Transition in PEPFAR-supported Countries
  • Session 9: Prevention in Men
    • Session 9AHIV Prevention in Men 
    • Session 9BScaling up oral PrEP for men in Kenya
    • Session 9CInterventions to decrease glans injuries, other safety and training updates
    • Session 9DMaximizing Prevention in Men: Successful Strategies to Increase Uptake of VMMC Among High-Risk Men
    • Session 9EVoluntary Medical Male Circumcision: Lessons in Sustainability
    • Session 9FPrivate Sector Engagement for Sustaining HIV Goods & Services in Vietnam
  • Session 10: Prevention in Adolescent Girls and Young Women – DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored and Safe)
    • Session 10ADREAMS Update: Progress & Future Directions 
    • Session 10BEarly lessons from DREAMS impact evaluations
    • Session 10CViolence against women and HIV
    • Session 10DHIV Prevention in the Hands of Adolescent Girls and Young Women: Acceptability & feasibility of oral PrEP in Tanzania
  • Session 11: DREAMS Private Sector Panel
  • Session 12: HIV Prevention & Treatment – What’s New? What’s Coming?
    • Session 12AInjectables for HIV Prevention and Treatment
    • Session 12BPreventing HIV during pregnancy & postpartum
    • Session 12CNew Technologies for Prevention: MPTS and Implants
    • Session 12DReducing Loss to Follow Up in the Botswana Combination Prevention Project
    • Session 12EDapivirine Vaginal Ring: Results, Regulatory Status, Next Steps
    • Session 12FFrameworks for PrEP Scale-Up
    • Session 12GManagement of Patients with Advanced HIV Disease: Diagnostics and Coming Attractions
  • Session 13: Local Partnerships – Listening to Local Voices and Supporting Local Organizations for Sustainable Epidemic Control
    • Session 13A: Local Partnerships: Listening to Local Voices and Funding Local Organizations for Sustainable Epidemic Control
    • Session 13BTransition: From a Field Office to a Vibrant, Successful Independent Zambian Organization
    • Session 13CScore Card and Community Level Advocacy
    • Session 13DCommunity financing for KP Organizations: experience from Thailand
    • Session 13EListening to local voices: Country-specific case study of implementation of the PLHIV Stigma Index - Uganda 
  • Closing Plenary: Making the Impossible Possible